‘Leading private equity firm Direct Capital has acquired a shareholding of 51% in New Zealand Pharmaceuticals (NZP), which produces specialty chemicals for some of the world’s leading pharmaceutical and biotechnology companies.

Direct Capital’s investment has been completed from its DCPIII and Pohutukawa private equity funds and from BioPacificVentures (BPV), allowing Direct Capital to combine its traditional private equity strength with BPV’s specialist industry expertise.’

Read more at Direct Capital acquires 51% of NZ Pharmaceuticals

Recent Entries

• Sigma Pharmaceuticals year profit rises 27 pct
• South African citizens cheap drug guinea pigs
• Two drugs test victims face a year in coma
• Can drug companies improve their reputation?
• Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
• Pfizer’s Forecast Disappoints
• Pharmaceutical RFID Adoption Stalls
• Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
• GlaxoSmithKline unveils best results since merger
• Pfizer Sues Teva, Sandoz Over Zithromax

This entry was posted on Thursday, November 24th, 2005 at 9:02 pm and is filed under General. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.